(Q35120585)

6 August 2017

The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses (English)

1 reference

6 August 2017

1 reference

ChEBI release 2020-05-28

Arne Ring

1

1 reference

6 August 2017

Arne Ring

2

1 reference

6 August 2017

Andreas Port

3

1 reference

6 August 2017

E Ulrike Graefe-Mody

4

1 reference

6 August 2017

Ivette Revollo

5

1 reference

6 August 2017

Mario Iovino

6

1 reference

6 August 2017

Klaus A Dugi

7

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

British Journal of Clinical Pharmacology

6 August 2017

1 reference

6 August 2017

72

1 reference

6 August 2017

1

1 reference

6 August 2017

39-50

1 reference

Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation.

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

Statistical characterization of QT prolongation

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

Facts, fancies and follies of drug-induced QT/QTc interval shortening

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

QT Prolongation and Fatal Arrhythmias: A Review of Clinical Implications and Effects of Drugs

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

Cardiac effects of ebastine and other antihistamines in humans

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

9 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03931.X

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03931.X

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03931.X

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03931.X

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03931.X

Effects of three fluoroquinolones on QT interval in healthy adults after single doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03931.X

Statistical issues including design and sample size calculation in thorough QT/QTc studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03931.X

Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03931.X

Statistical models for heart rate correction of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03931.X

A maximum likelihood approach for estimating the QT correction factor using mixed effects model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03931.X

Bias and variance evaluation of QT interval correction methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03931.X

Differences between study-specific and subject-specific heart rate corrections of the QT interval in investigations of drug induced QTc prolongation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03931.X

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3141185

Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects

27 September 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03931.X

Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21306414

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1365-2125.2011.03931.X

1 reference

6 August 2017

1 reference

6 August 2017

1 reference